Prosecution Insights
Last updated: April 19, 2026

UCB Biopharma SRL

14 pending office actions

Portfolio Summary

14
Total Pending OAs
3
Final Rejections
11
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18703675 FORMULATIONS VIGIL, TORIANA NICHOLE 1612 Non-Final OA Apr 22, 2024
18703661 FORMULATIONS VIGIL, TORIANA NICHOLE 1612 Non-Final OA Apr 22, 2024
18632964 Imaging Agents DONOHUE, SEAN R 1618 Non-Final OA Apr 11, 2024
18282554 FORMULATIONS COMPRISING A THERAPEUTIC PROTEIN AND AT LEAST ONE STABILIZER KWON, JOHN SEUNGJAI 1615 Non-Final OA Sep 18, 2023
18344945 TAU-BINDING ANTIBODIES WEIDNER, ADAM M 1675 Non-Final OA Jun 30, 2023
18344930 TAU-BINDING ANTIBODIES WEIDNER, ADAM M 1675 Non-Final OA Jun 30, 2023
18267235 IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS WILLIS, DOUGLAS M 1624 Non-Final OA Jun 14, 2023
18039498 FORMULATIONS SCOTLAND, REBECCA LYNN 1615 Final Rejection May 31, 2023
18021005 GENE THERAPY USING NUCLEIC ACID CONSTRUCTS COMPRISING METHYL CPG BINDING PROTEIN 2 (MECP2) PROMOTER SEQUENCES THUESON, HANNA MARIE 1638 Non-Final OA Feb 13, 2023
18152872 Pharmaceutical Formulations KIM, YUNSOO 1641 Non-Final OA Jan 11, 2023
18045597 Methods of Treatment Using Anti-IL-17A/F Antibodies JIANG, DONG 1674 Non-Final OA Oct 11, 2022
17907116 AUTONOMOUS KNOB DOMAIN PEPTIDES ALFANO, ALAN 1641 Non-Final OA Sep 23, 2022
17787094 MULTI-SPECIFIC ANTIBODIES CHATTIN, AMY MARIE 1643 Final Rejection Jun 17, 2022
17286247 METHOD FOR THE TREATMENT OF MYASTHENIA GRAVIS HOLTZMAN, KATHERINE ANN 1646 Final Rejection Apr 16, 2021

Managing UCB Biopharma SRL's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month